KR20210099606A - 바이로좀을 포함하는 경구 분산성 백신 - Google Patents

바이로좀을 포함하는 경구 분산성 백신 Download PDF

Info

Publication number
KR20210099606A
KR20210099606A KR1020217020127A KR20217020127A KR20210099606A KR 20210099606 A KR20210099606 A KR 20210099606A KR 1020217020127 A KR1020217020127 A KR 1020217020127A KR 20217020127 A KR20217020127 A KR 20217020127A KR 20210099606 A KR20210099606 A KR 20210099606A
Authority
KR
South Korea
Prior art keywords
dosage form
virosome
formulation
freeze
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217020127A
Other languages
English (en)
Korean (ko)
Inventor
익 텡 웡
찰리 스마든
코자스테 쉬르카니
마리오 아마커
실바인 플로이리
안토니우스 요하네스 헨드리쿠스 슈테그만
Original Assignee
카탈렌트 유.케이. 스윈던 지디스 리미티드
마이메틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카탈렌트 유.케이. 스윈던 지디스 리미티드, 마이메틱스 코포레이션 filed Critical 카탈렌트 유.케이. 스윈던 지디스 리미티드
Priority to KR1020237038419A priority Critical patent/KR20230159621A/ko
Publication of KR20210099606A publication Critical patent/KR20210099606A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217020127A 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신 Ceased KR20210099606A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237038419A KR20230159621A (ko) 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772823P 2018-11-29 2018-11-29
US62/772,823 2018-11-29
PCT/EP2019/082940 WO2020109485A1 (en) 2018-11-29 2019-11-28 Oral dispersible vaccine comprising virosomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038419A Division KR20230159621A (ko) 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신

Publications (1)

Publication Number Publication Date
KR20210099606A true KR20210099606A (ko) 2021-08-12

Family

ID=68766733

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217020127A Ceased KR20210099606A (ko) 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신
KR1020237038419A Pending KR20230159621A (ko) 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237038419A Pending KR20230159621A (ko) 2018-11-29 2019-11-28 바이로좀을 포함하는 경구 분산성 백신

Country Status (14)

Country Link
US (2) US11523988B2 (https=)
EP (1) EP3886896B1 (https=)
JP (2) JP7408660B2 (https=)
KR (2) KR20210099606A (https=)
CN (1) CN113301917B (https=)
AR (1) AR117671A1 (https=)
AU (1) AU2019389772A1 (https=)
CA (1) CA3120744A1 (https=)
ES (1) ES2993361T3 (https=)
IL (1) IL282371B2 (https=)
MX (1) MX2021006153A (https=)
TW (1) TWI819156B (https=)
WO (1) WO2020109485A1 (https=)
ZA (1) ZA202104459B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
IL309143A (en) * 2021-06-11 2024-02-01 Orphai Therapeutics Inc Stabilized apilimod compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086831C (en) 1991-05-08 1999-03-16 Reinhard Gluck Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
WO1997013531A1 (en) 1995-10-13 1997-04-17 Zynaxis, Inc. Solid, orally administrable viral vaccines and methods of preparation
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
AU2001234616A1 (en) * 2000-01-31 2001-08-07 Vic Jira Vaccine composition, process and methods
EP1447080A1 (en) 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
EP1652914A1 (en) 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
EP1797895A1 (en) 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
AR059972A1 (es) 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
US20100047277A1 (en) 2006-07-13 2010-02-25 Compans Richard W Virosomes, methods of preparation, and immunogenic compositions
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
EP1938835A1 (en) 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
KR20100045413A (ko) 2007-06-14 2010-05-03 크루셀 스위츨랜드 아게 피내 인플루엔자 백신
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EP2058002A1 (en) 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
EP2519539A4 (en) 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
GB201005976D0 (en) 2010-04-09 2010-05-26 Univ Aston A freeze-dried tablet
JP2013542928A (ja) 2010-09-30 2013-11-28 フランバックス ソチエタ レスポンサビリタ リミテ ビロソーム粒子の生成
HUE052853T2 (hu) 2010-10-08 2021-05-28 Scherer Technologies Llc R P Orális vakcina gyorsan oldódó dózisforma, keményítõ alkalmazásával
CN107625958A (zh) 2011-05-17 2018-01-26 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
CN105636609A (zh) 2013-10-25 2016-06-01 白血球保健股份有限公司 一种新颖的生产稳定疫苗的方法
AU2014368594B2 (en) 2013-12-19 2020-03-05 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
US10532093B2 (en) 2014-07-18 2020-01-14 Mds Wellcome Trust Hilleman Laboratories Pvt. Ltd. Thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
WO2016039620A2 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
WO2017047089A1 (en) 2015-09-16 2017-03-23 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions

Also Published As

Publication number Publication date
EP3886896C0 (en) 2024-09-25
CA3120744A1 (en) 2020-06-04
EP3886896B1 (en) 2024-09-25
EP3886896A1 (en) 2021-10-06
US11224571B2 (en) 2022-01-18
MX2021006153A (es) 2021-08-16
JP7408660B2 (ja) 2024-01-05
WO2020109485A1 (en) 2020-06-04
US20210386660A1 (en) 2021-12-16
ES2993361T3 (en) 2024-12-27
AR117671A1 (es) 2021-08-25
CN113301917B (zh) 2025-04-29
JP2022510372A (ja) 2022-01-26
US20200170933A1 (en) 2020-06-04
TWI819156B (zh) 2023-10-21
ZA202104459B (en) 2026-03-25
US11523988B2 (en) 2022-12-13
JP2024029053A (ja) 2024-03-05
KR20230159621A (ko) 2023-11-21
TW202038904A (zh) 2020-11-01
AU2019389772A1 (en) 2021-07-22
BR112021010290A2 (pt) 2021-08-17
CN113301917A (zh) 2021-08-24
IL282371A (en) 2021-06-30
IL282371B2 (en) 2025-03-01
IL282371B1 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
EP2709657B1 (en) Thermostable vaccine compositions and methods of preparing same
JP2024029053A (ja) ビロソームを含む経口分散性ワクチン
US8216588B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2015163652A (ja) 抗原−アジュバント組成物および方法
US11559577B2 (en) Immunogenic composition forming a vaccine, and a method for its manufacture
PL210707B1 (pl) Liofilizowana nie sprasowana szybko dyspergująca stała postać dawkowania
US11278617B2 (en) Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
WO2022011332A2 (en) Immunogenic composition forming a vaccine, and a method for its manufacture
RU2808276C2 (ru) Перорально диспергируемая вакцина, содержащая виросомы
HK40049705A (en) Oral dispersible vaccine comprising virosomes
HK40049705B (zh) 包含病毒体的可经口分散疫苗
US20180161283A1 (en) Methods and products for treating and/or delaying onset of dysplastic lesions
BR122023000645B1 (pt) Usos de forma de dosagem de vacina sólida oral
BR112021010290B1 (pt) Forma de dosagem de vacina sólida oral e seus métodos de formação
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
HK1196265B (en) Thermostable vaccine compositions and methods of preparing same
HK1196265A (en) Thermostable vaccine compositions and methods of preparing same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210628

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221118

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20221118

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230407

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230807

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230407

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I